Investigations into the efficacy of multi-component cocaine vaccines

• Published in: Bioorganic & medicinal chemistry letters Vol. 28; no. 16; pp. 2779 - 2783
• Main Authors: Kimishima, Atsushi, Olson, Margaret E., Janda, Kim D.
• Format: Journal Article
• Language: English
• Published: OXFORD Elsevier Ltd 01.09.2018; Elsevier
• Subjects: Addiction; Adjuvant; Adjuvants, Immunologic; Animals; Antigen-Antibody Reactions; Chemistry; Chemistry, Medicinal; Chemistry, Organic; Cocaine; Cocaine - antagonists & inhibitors; Cocaine - immunology; Cocaine - pharmacology; CpG ODN 1826; Injections, Intraperitoneal; Life Sciences & Biomedicine; Locomotion - drug effects; Mice; Molecular Structure; Ovalbumin - immunology; Pharmacology & Pharmacy; Physical Sciences; Science & Technology; Vaccine; Vaccines - administration & dosage; Vaccines - biosynthesis; Vaccines - immunology; CpG ODN 1826; Vaccine; Cocaine; Adjuvant; Addiction; B SURFACE-ANTIGEN; CPG DNA; HAPTEN DESIGN; DEPENDENCE; CONJUGATION; IMMUNOSTIMULATORY DNA; SUBSTANCE-USE DISORDERS; IMMUNE-RESPONSES; DOUBLE-BLIND; DISRUPTED ADENOVIRUS
• ISSN: 0960-894X; 1464-3405
• DOI: 10.1016/j.bmcl.2017.12.043

[Display omitted] Although cocaine addiction remains a serious health and societal problem in the United States, no FDA-approved treatment has been developed. Vaccines offer an exciting strategy for the treatment of cocaine addiction; however, vaccine formulations need to be optimized to improve efficacy. Herein, we examine the effectiveness of a tricomponent cocaine vaccine, defined as having its hapten (GNE) and adjuvant (cytosine-guanine oligodeoxynucleotide 1826, CpG ODN 1826) covalently linked via the immunogenic protein ovalbumin (OVA). The tricomponent vaccine (GNE-OVA-CpG 1826) and a vaccine of analogous, individual components (GNE-OVA+CpG ODN 1826) were found to similarly induce highly specific anticocaine antibody production in mice and block cocaine’s stimulant effects in hyperlocomotor testing.